Youyong Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Youyong Yuan has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Department of Chemical and Biomolecular Engineering National University of Singapore Singapore Singapore
37 shared publications Qingyu Zong
School of Biomedical Sciences and Engineering Guangzhou International Campus South China University of Technology Guangzhou 511442 P.R. China
23 shared publicationsYe Liu
School of Biomedical Sciences and Engineering Guangzhou International Campus South China University of Technology Guangzhou People's Republic of China
23 shared publicationsIhsan Ullah
South China University of Technology, Guangzhou International Campus
22 shared publications- Jun Wang
School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P. R. China
20 shared publications Kewei Wang
19 shared publications
Latest Publications
- 14 September 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 225, 259-276
Proteolysis-Targeting Chimera-Loaded Hydrogel Dressings Orchestrate Immunoregulation and Angiogenesis to Promote Tissue Regeneration in Large Diabetic Wounds
- 14 September 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 225, 259-276
Proteolysis-Targeting Chimera-Loaded Hydrogel Dressings Orchestrate Immunoregulation and Angiogenesis to Promote Tissue Regeneration in Large Diabetic Wounds
- 13 September 2026
- Published by Springer Nature
- p. 1-33
Techniques for Accelerating the Understanding of PROTAC-Based Ternary Complex
- 13 September 2026
- Published by Springer Nature
- p. 1-33
Techniques for Accelerating the Understanding of PROTAC-Based Ternary Complex
- Open Access
- 31 August 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (79) , e77935
Transdermal STING Degradation Reprograms Innate‐Adaptive Immunity Crosstalk for Relapse‐Free Psoriasis and Comorbid Arthritis Therapy
Psoriasis is a chronic inflammatory disorder in which current therapies provide only transient symptomatic relief by suppressing pathogenic immune responses, while the restoration of immune homeostasis and prevention of relapse or comorbid arthritis remain unaddressed. Here, we present a microneedle‐based transdermal platform incorporating reactive oxygen species (ROS)‐responsive self‐immolative polymers (SIPs) to encapsulate a proteolysis‐targeting chimera (PROTAC) for selective degradation of stimulator of interferon genes (STING), a central regulator of innate immunity. Upon insertion into psoriatic skin, the SIPs are deposited into the dermis and undergo ROS‐triggered self‐immolation, releasing carbonyl sulfide, which is enzymatically converted into hydrogen sulfide (H 2 S), exerting local anti‐inflammatory and anti‐oxidant effects to relieve epidermal hyperplasia. Simultaneously, STING‐targeting PROTAC are internalized by dendritic cells and macrophages promoting targeted STING degradation and reprogramming the immune microenvironment. This dual mechanism suppresses innate immunity via M2 macrophage polarization and modulates adaptive responses by inducing tolerogenic dendritic cells to reducing skin‐resident memory T cells, thereby preventing epidermal hyperplasia and recurrence caused by immune stress. In imiquimod (IMQ)‐induced psoriasis, relapse, and psoriatic arthritis models, this strategy achieved durable remission and restored immune homeostasis, establishing a rationally engineered transdermal therapy for the long‐term management of psoriasis and its systemic complications.
- 31 August 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (79) , e77935
Open AccessTransdermal STING Degradation Reprograms Innate‐Adaptive Immunity Crosstalk for Relapse‐Free Psoriasis and Comorbid Arthritis Therapy
Psoriasis is a chronic inflammatory disorder in which current therapies provide only transient symptomatic relief by suppressing pathogenic immune responses, while the restoration of immune homeostasis and prevention of relapse or comorbid arthritis remain unaddressed. Here, we present a microneedle‐based transdermal platform incorporating reactive oxygen species (ROS)‐responsive self‐immolative polymers (SIPs) to encapsulate a proteolysis‐targeting chimera (PROTAC) for selective degradation of stimulator of interferon genes (STING), a central regulator of innate immunity. Upon insertion into psoriatic skin, the SIPs are deposited into the dermis and undergo ROS‐triggered self‐immolation, releasing carbonyl sulfide, which is enzymatically converted into hydrogen sulfide (H 2 S), exerting local anti‐inflammatory and anti‐oxidant effects to relieve epidermal hyperplasia. Simultaneously, STING‐targeting PROTAC are internalized by dendritic cells and macrophages promoting targeted STING degradation and reprogramming the immune microenvironment. This dual mechanism suppresses innate immunity via M2 macrophage polarization and modulates adaptive responses by inducing tolerogenic dendritic cells to reducing skin‐resident memory T cells, thereby preventing epidermal hyperplasia and recurrence caused by immune stress. In imiquimod (IMQ)‐induced psoriasis, relapse, and psoriatic arthritis models, this strategy achieved durable remission and restored immune homeostasis, establishing a rationally engineered transdermal therapy for the long‐term management of psoriasis and its systemic complications.
- Open Access
- 13 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77162
Self‐Amplified Activatable Fluorescent Probe for Early Diagnosis of Acute Kidney Injury and High‐Throughput Screening of Natural Protectants
Early diagnosis of acute kidney injury (AKI) and identification of effective therapeutics remain significant clinical challenges. Herein, we developed an activatable near‐infrared fluorescent nanoprobe (denoted PS‐QRC) by encapsulating a self‐amplifying fluorescent sensor (QRCy) within kidney‐targetable L ‐serine‐functionalized ultrasmall poly(amidoamine) (PAMAM‐Ser) dendrimers. Upon activation by reactive oxygen species (ROS), QRCy undergoes self‐fragmentation, releasing four fluorophores to amplify the fluorescence signal, affording an ultra‐low detection limit of 81 nM for hydrogen peroxide. The L ‐serine modification enables specific binding of PS‐QRC to kidney injury molecule‐1 (KIM‐1), which is overexpressed in injured renal tubules, thereby promoting renal accumulation and reducing background interference. Impressively, PS‐QRC allows noninvasive real‐time imaging of cisplatin‐induced AKI in mice as early as 12 h, significantly earlier than conventional serum biochemical and histopathological analyses. Furthermore, a high‐throughput screening platform was established using this nanoprobe to evaluate natural products, from which chrysin was identified as a promising renoprotective agent. Chrysin demonstrated both in vitro and in vivo renoprotective effects, with efficacy comparable to the established antioxidant N ‐acetylcysteine. Moreover, PS‐QRC enabled quantitative monitoring of chrysin's dose‐dependent therapeutic response. Overall, this integrated probe provides a sensitive and reliable tool for early AKI diagnosis and the high‐throughput discovery of novel renoprotective drugs.
- 13 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77162
Open AccessSelf‐Amplified Activatable Fluorescent Probe for Early Diagnosis of Acute Kidney Injury and High‐Throughput Screening of Natural Protectants
Early diagnosis of acute kidney injury (AKI) and identification of effective therapeutics remain significant clinical challenges. Herein, we developed an activatable near‐infrared fluorescent nanoprobe (denoted PS‐QRC) by encapsulating a self‐amplifying fluorescent sensor (QRCy) within kidney‐targetable L ‐serine‐functionalized ultrasmall poly(amidoamine) (PAMAM‐Ser) dendrimers. Upon activation by reactive oxygen species (ROS), QRCy undergoes self‐fragmentation, releasing four fluorophores to amplify the fluorescence signal, affording an ultra‐low detection limit of 81 nM for hydrogen peroxide. The L ‐serine modification enables specific binding of PS‐QRC to kidney injury molecule‐1 (KIM‐1), which is overexpressed in injured renal tubules, thereby promoting renal accumulation and reducing background interference. Impressively, PS‐QRC allows noninvasive real‐time imaging of cisplatin‐induced AKI in mice as early as 12 h, significantly earlier than conventional serum biochemical and histopathological analyses. Furthermore, a high‐throughput screening platform was established using this nanoprobe to evaluate natural products, from which chrysin was identified as a promising renoprotective agent. Chrysin demonstrated both in vitro and in vivo renoprotective effects, with efficacy comparable to the established antioxidant N ‐acetylcysteine. Moreover, PS‐QRC enabled quantitative monitoring of chrysin's dose‐dependent therapeutic response. Overall, this integrated probe provides a sensitive and reliable tool for early AKI diagnosis and the high‐throughput discovery of novel renoprotective drugs.
- 29 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 398, 115217
Drug-likeness defects drive carrier-free cyanine–PROTAC self-assembly for tumor-specific protein degradation
- 29 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 398, 115217
Drug-likeness defects drive carrier-free cyanine–PROTAC self-assembly for tumor-specific protein degradation
- 24 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (26) , 27869-27883
Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is sustained by a self-amplifying pathological circuit involving senescence-associated epithelial injury and fibroblast activation, which together drive persistent inflammatory signaling, excessive extracellular matrix deposition, and progressive loss of lung function. Although proteolysis-targeting chimeras (PROTACs) offer a powerful approach to eliminate disease-driving proteins, their application in fibrotic lung disease remains limited by inefficient pulmonary delivery, poor lesion retention, and insufficient intervention in multicellular profibrotic networks. Herein, we develop an inhalable enzyme-activated polymeric PROTAC nanococktail that enables concurrent degradation of two key profibrotic signaling regulators in fibrotic lungs. The nanococktail consists of GAL@SD and FAP@BD, two disease-microenvironment-responsive nanoparticles carrying distinct PROTAC cargos. GAL@SD responds to elevated senescence-associated β-galactosidase activity in fibrotic lungs and releases a stimulator of interferon genes (STING)-degrading PROTACs to suppress senescence-associated inflammatory signaling linked to impaired alveolar epithelial repair. FAP@BD is activated by fibroblast activation protein-α enriched in activated fibroblast-dominated fibrotic regions, delivering a bromodomain-containing protein 4 (BRD4)-degrading PROTAC to inhibit myofibroblast activation and extracellular matrix production. After inhalation, both nanoparticles exhibit efficient mucus penetration, improved pulmonary retention, and preferential accumulation in fibrotic lesions, enabling localized degradation of STING and BRD4. In a bleomycin-induced mouse model of pulmonary fibrosis, the combined PROTAC nanococktail achieves superior therapeutic efficacy compared with either single PROTAC nanoparticle, as demonstrated by restored lung architecture, improved respiratory function, reduced collagen deposition, and reversal of fibrosis-associated transcriptional programs. These results demonstrate an inhaled dual-PROTAC nanotherapeutic strategy for simultaneously attenuating epithelial senescence-associated inflammation and fibroblast-driven matrix remodeling.
- 24 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (26) , 27869-27883
Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is sustained by a self-amplifying pathological circuit involving senescence-associated epithelial injury and fibroblast activation, which together drive persistent inflammatory signaling, excessive extracellular matrix deposition, and progressive loss of lung function. Although proteolysis-targeting chimeras (PROTACs) offer a powerful approach to eliminate disease-driving proteins, their application in fibrotic lung disease remains limited by inefficient pulmonary delivery, poor lesion retention, and insufficient intervention in multicellular profibrotic networks. Herein, we develop an inhalable enzyme-activated polymeric PROTAC nanococktail that enables concurrent degradation of two key profibrotic signaling regulators in fibrotic lungs. The nanococktail consists of GAL@SD and FAP@BD, two disease-microenvironment-responsive nanoparticles carrying distinct PROTAC cargos. GAL@SD responds to elevated senescence-associated β-galactosidase activity in fibrotic lungs and releases a stimulator of interferon genes (STING)-degrading PROTACs to suppress senescence-associated inflammatory signaling linked to impaired alveolar epithelial repair. FAP@BD is activated by fibroblast activation protein-α enriched in activated fibroblast-dominated fibrotic regions, delivering a bromodomain-containing protein 4 (BRD4)-degrading PROTAC to inhibit myofibroblast activation and extracellular matrix production. After inhalation, both nanoparticles exhibit efficient mucus penetration, improved pulmonary retention, and preferential accumulation in fibrotic lesions, enabling localized degradation of STING and BRD4. In a bleomycin-induced mouse model of pulmonary fibrosis, the combined PROTAC nanococktail achieves superior therapeutic efficacy compared with either single PROTAC nanoparticle, as demonstrated by restored lung architecture, improved respiratory function, reduced collagen deposition, and reversal of fibrosis-associated transcriptional programs. These results demonstrate an inhaled dual-PROTAC nanotherapeutic strategy for simultaneously attenuating epithelial senescence-associated inflammation and fibroblast-driven matrix remodeling.
- 14 May 2026
- Published by Springer Nature in Chinese Journal of Polymer Science
- Vol. 44 (7) , 1-24
Tumor Microenvironment-responsive Self-immolative Polymers for Cancer Imaging and Therapy
- 14 May 2026
- Published by Springer Nature in Chinese Journal of Polymer Science
- Vol. 44 (7) , 1-24
Tumor Microenvironment-responsive Self-immolative Polymers for Cancer Imaging and Therapy
- 20 April 2026
- Published by Elsevier in Biomaterials
- Vol. 333, 124236
Catch and light up: Dual bioorthogonal reactions actualize fluorescent probe retention and activation for surgical navigation
- 20 April 2026
- Published by Elsevier in Biomaterials
- Vol. 333, 124236
Catch and light up: Dual bioorthogonal reactions actualize fluorescent probe retention and activation for surgical navigation
- Open Access
- 27 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (9) , eado7448
PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity
Activation of the stimulator of interferon genes (STING) pathway drives natural killer (NK) cells and T cells to orchestrate multidimensional antitumor immune responses. While cytosolic DNA accumulation represents a superior endogenous strategy for STING activation, DNA repair machinery substantially constrains its immunogenic potential. Here, we propose a promising therapeutic strategy that leverages proteolysis-targeting chimera (PROTAC)–mediated degradation of PARP1 [poly(ADP-ribose) polymerase 1] and BRD4 (bromodomain-containing protein 4) to induce synthetic lethality, thereby disrupting DNA repair machinery that drives nuclear-to-cytosolic DNA leakage, surpassing the STING activation threshold to ignite cGAS-STING–mediated innate immunity. Our strategy demonstrates superior antitumor efficacy across multiple tumor models, eliciting robust CD8 + T cell– and NK cell–mediated immunity while suppressing pulmonary metastasis progression. This strategic integration of synthetic lethality with an immunogenic stress response establishes a previously unidentified paradigm for expanding broad applications by cGAS-STING–mediated innate immunity.
- 27 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (9) , eado7448
Open AccessPROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity
Activation of the stimulator of interferon genes (STING) pathway drives natural killer (NK) cells and T cells to orchestrate multidimensional antitumor immune responses. While cytosolic DNA accumulation represents a superior endogenous strategy for STING activation, DNA repair machinery substantially constrains its immunogenic potential. Here, we propose a promising therapeutic strategy that leverages proteolysis-targeting chimera (PROTAC)–mediated degradation of PARP1 [poly(ADP-ribose) polymerase 1] and BRD4 (bromodomain-containing protein 4) to induce synthetic lethality, thereby disrupting DNA repair machinery that drives nuclear-to-cytosolic DNA leakage, surpassing the STING activation threshold to ignite cGAS-STING–mediated innate immunity. Our strategy demonstrates superior antitumor efficacy across multiple tumor models, eliciting robust CD8 + T cell– and NK cell–mediated immunity while suppressing pulmonary metastasis progression. This strategic integration of synthetic lethality with an immunogenic stress response establishes a previously unidentified paradigm for expanding broad applications by cGAS-STING–mediated innate immunity.
- Open Access
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Catch and Light Up: Dual Bioorthogonal Reactions Actualize Fluorescent Probe Retention and Activation for Surgical Navigation
Fluorescent molecular probes are promising imaging tools for tumor surgical navigation. However, achieving both precise diagnosis and long-term surgical navigation in complex tumor environments remains challenging. In this study, we developed a “catch and light-up” fluorescent probe (CyTB) that enables specific fluorescence retention and activation, thereby enhancing imaging navigation accuracy. The probe consists of a hemicyanine unit as the near-infrared fluorescence signal reporter, tetrazine (Tz) reactive group bicyclo[6.1.0]nonyne (BCN) and trans-cyclooctene (TCO). Once arrival at the tumor site labeled by Tz in advance, the BCN group of probes was anchored through ligation reaction to enhance the probe retention. Concurrently, the TCO group can rapidly be cleaved by Tz leading to the light-up of fluorescence. The retention time of the probe at the tumor site can reach 130 h, while the tumor-to-normal tissue ratio in metastatic microtumor of pancreatic cancer (<2 mm) still reaches 6.5, enabling efficient tumor tracking and precise marginal resection, thus providing a promising strategy for surgical navigation.
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCatch and Light Up: Dual Bioorthogonal Reactions Actualize Fluorescent Probe Retention and Activation for Surgical Navigation
Fluorescent molecular probes are promising imaging tools for tumor surgical navigation. However, achieving both precise diagnosis and long-term surgical navigation in complex tumor environments remains challenging. In this study, we developed a “catch and light-up” fluorescent probe (CyTB) that enables specific fluorescence retention and activation, thereby enhancing imaging navigation accuracy. The probe consists of a hemicyanine unit as the near-infrared fluorescence signal reporter, tetrazine (Tz) reactive group bicyclo[6.1.0]nonyne (BCN) and trans-cyclooctene (TCO). Once arrival at the tumor site labeled by Tz in advance, the BCN group of probes was anchored through ligation reaction to enhance the probe retention. Concurrently, the TCO group can rapidly be cleaved by Tz leading to the light-up of fluorescence. The retention time of the probe at the tumor site can reach 130 h, while the tumor-to-normal tissue ratio in metastatic microtumor of pancreatic cancer (<2 mm) still reaches 6.5, enabling efficient tumor tracking and precise marginal resection, thus providing a promising strategy for surgical navigation.